Adenoma Detection Rate in Colonoscopy Performed With EndoRings
Adenoma Detection Rate in Colonoscopy Performed With EndoRings - a Single-centre Prospective Randomised Clinical Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Colonoscopy is recognised as the standard method for finding and removing colorectal adenomas, which are precursors of most colorectal cancers. It has been shown that there is a direct correlation between adenoma detection rate and the risk of developing colorectal cancer subsequently. However, patients undergoing colonoscopy are still at risk of developing colorectal cancer, mainly because precursor lesions are missed during the procedure. This may be due to insufficient bowel preparation, difficulties in visualising flat lesions or the location of lesions behind haustral folds.
Improving the ADR can be achieved by different means; better training of endoscopists, improved bowel preparation, optimal sedation and medico technical developments. The technical improvements have mainly been in the optimising of image and improved scope thickness and flexibility, including devices that improve visualisation by increasing the exposed colonic surface . One of these new inventions is the EndoRings II Distal Attachment.
According to the Danish Colorectal Cancer Screening Database, the ADR of standard screening colonoscopy is between 34 and 67 % with a national average of 49 % of patients with detected adenomas. Due to the known adenoma miss rate in standard screening colonoscopies, it is important to increase the ADR on average as well as finding ways to improve ADR for centres with a lower than average ADR.
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Køge, Denmark, 4600
- Zealand University Hospital Køge, Department of Surgery
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patients meeting all the below listed criteria are eligible for inclusion in the trial:
- Age between 50 - 74 years (age range of screening population)
- Positive HemoCult home test from the Danish Colorectal Cancer Screening Programme
- Ability to give informed consent to participation in the trial.
Exclusion Criteria:
Patients meeting one or more of the below listed criteria will be excluded from the trial:
- History of colorectal cancer
- History of Inflammatory Bowel Disease
- Part of other control programme (e.g. HNPCC or adenoma control)
- ASA =/> 4 and/or necessity of general anaesthesia
- Former surgery with removal of a part of the colon on either benign or malignant background
Study Plan
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
ACTIVE_COMPARATOR: With EndoRings
Colonoscopy is performed with the use of the cap-device EndoRings II Distal Attachment to be attached to the tip of the colonoscope
|
Colonoscopy cap
|
|
NO_INTERVENTION: NO EndoRings
Colonoscopy is performed conventionally without any caps
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adenoma detection rate
Time Frame: maximum 60 minutes
|
Number of colorectal adenomas/neoplasms/carcinomas found in colonoscopy
|
maximum 60 minutes
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Completion time
Time Frame: maximum 60 minutes
|
Overall colonoscopy duration
|
maximum 60 minutes
|
|
Completion rate
Time Frame: maximum 60 minutes
|
Colonoscopy completion (intubation to coecum)
|
maximum 60 minutes
|
|
Malignancy detection
Time Frame: maximum 60 minutes
|
Number of colorectal malignancies found in colonoscopy
|
maximum 60 minutes
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Line E Line, MD, Zealand University Hospital Køge
- Study Director: Ismayil Gögenur, Prof, DMSc, Zealand University Hospital Køge
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Adenoma
Other Study ID Numbers
Other Study ID Numbers
- ZUH-KØGE-KIR1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Neoplasms
-
NCT03428958CompletedColorectal Neoplasms | Colorectal Cancer | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, Colorectal
-
NCT05200442SuspendedColorectal Cancer | Colorectal Cancer Metastatic | Colorectal Adenocarcinoma | Advanced Colorectal Carcinoma | Advanced Colorectal Adenocarcinoma
-
NCT03800602CompletedColorectal Cancer Metastatic | Colorectal Adenocarcinoma | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Refractory Colorectal Carcinoma | Metastatic Microsatellite Stable Colorectal Carcinoma | Stage IVC Colorectal Cancer
-
NCT06342401RecruitingColorectal Neoplasms | Colorectal Cancer | Colorectal Adenocarcinoma | Colorectal Cancer Stage II | Colorectal Cancer Stage III | Colorectal Cancer Stage IV | Colorectal Neoplasms Malignant | Colorectal Cancer Stage I
-
NCT01139138CompletedColorectal Cancer | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, Colorectal
-
NCT00478634CompletedColorectal Cancer | Colorectal Tumors | Colorectal Carcinoma | Neoplasms, Colorectal
-
NCT04148378WithdrawnColorectal Neoplasms | Colorectal Cancer | Colorectal Cancer Metastatic | Colorectal Carcinoma | Colorectal Adenocarcinoma | Colorectal Sarcoma
-
NCT07147231RecruitingMetastatic Colorectal Adenocarcinoma | Refractory Colorectal Adenocarcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Unresectable Colorectal Adenocarcinoma
-
NCT07621757Enrolling by invitationColorectal Cancer | Colorectal Adenoma | Colorectal Polyp
-
NCT03377361CompletedColorectal Cancer | Colorectal Neoplasm | Colorectal Tumors | Colorectal Carcinoma
Clinical Trials on EndoRings II Distal Attachment
-
NCT02472730CompletedEndoscopy, Gastrointestinal
-
NCT02243930Completed
-
NCT05784987Not yet recruitingDiffuse Large B-cell Lymphoma
-
NCT02329080CompletedDiffuse Large B-cell Lymphoma
-
NCT00335556CompletedClear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Clear Cell Sarcoma of the Kidney | Papillary Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Stage I Renal Cell Cancer | Childhood Renal Cell Carcinoma | Stage II Renal Cell Cancer | Stage I Renal Wilms Tumor
-
NCT00614588CompletedLaparoscopic Surgery | Surgery | General Anesthesia | Postoperative
-
NCT00439556CompletedHematopoietic and Lymphoid Cell Neoplasm | Lymphoma | CD20 Positive | Lymphocytic Neoplasm